 |
|
Prophylactic Antithrombotic Therapy for Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies
Do the Benefits Outweigh the Risks? A Decision Analysis
Denis G. Wahl, MD, PhD;
Henri Bounameaux, MD;
Philippe de Moerloose, MD;
François P. Sarasin, MD
Arch Intern Med. 2000;160:2042-2048.
Background A high incidence of both arterial and venous thromboembolic events has been reported in patients with systemic lupus erythematosus (SLE), but the risks and benefits of primary prophylactic antithrombotic therapy have not been assessed. We measured the clinical benefit of 3 antithrombotic regimens in patients with SLE without antiphospholipid antibodies, with anticardiolipin antibodies, or with lupus anticoagulant.
Methods A Markov decision analysis was used to evaluate prophylactic aspirin therapy, prophylactic oral anticoagulant therapy, and observation. Input data were obtained by literature review. Clinical practice was simulated in a hypothetical cohort of patients with SLE who had not experienced any previous episode of arterial or venous thromboembolic events. For each strategy, we measured numbers of thromboembolic events prevented and major bleeding episodes induced, and quality-adjusted survival years.
Results Prophylactic aspirin therapy was the preferred strategy in all settings, the number of prevented thrombotic events exceeding that of induced bleeding episodes. In the baseline analysis (40-year-old patients with SLE), the gain in quality-adjusted survival years achieved by prophylactic aspirin compared with observation ranged from 3 months in patients without antiphospholipid antibodies to 11 months in patients with anticardiolipin antibodies or lupus anticoagulant. Prophylactic oral anticoagulant therapy provided better results than prophylactic aspirin only in patients with lupus anticoagulant and an estimated bleeding risk of 1% per year or less.
Conclusions Prophylactic aspirin should be given to all patients with SLE to prevent both arterial and venous thrombotic manifestations, especially in patients with antiphospholipid antibodies. In selected patients with lupus anticoagulant and a low bleeding risk, prophylactic oral anticoagulant therapy may provide a higher utility.
From the Division of Angiology and Hemostasis (Drs Wahl, Bounameaux, and de Moerloose), and Clinique de Médecine 1 (Dr Sarasin), Department of Internal Medicine, Hôpitaux Universitaires de Genève, Geneva, Switzerland. Dr Wahl is now with the Service de Médecine Interne H, Centre Hospitalier Universitaire, Nancy, and Faculté de Médecine, Vandoeuvre-Les-Nancy, France.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies
Moore et al.
CLIN APPL THROMB HEMOST 2008;14:332-337.
ABSTRACT
Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort
Duran-Barragan et al.
Rheumatology (Oxford) 2008;47:1093-1096.
ABSTRACT
| FULL TEXT
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Hereng et al.
Lupus 2008;17:11-15.
ABSTRACT
Lupus and cardiovascular disease: the facts
Szekanecz and Shoenfeld
Lupus 2006;15:3-10.
ABSTRACT
Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus
Tincani et al.
Rheumatology (Oxford) 2006;45:iv8-iv13.
ABSTRACT
| FULL TEXT
Treatment of antiphospholipid antibody syndrome.
Wahl and Regnault
JAMA 2006;296:42-43.
FULL TEXT
Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus
Ruiz-Irastorza et al.
Lupus 2004;13:900-905.
ABSTRACT
Antiphospholipid Testing and Outcome--Reply
Ruiz-Irastorza et al.
Arch Intern Med 2004;164:1701-1702.
FULL TEXT
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Ozturk et al.
CLIN APPL THROMB HEMOST 2004;10:89-126.
ABSTRACT
High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus
Ruiz-Irastorza et al.
Arch Intern Med 2004;164:77-82.
ABSTRACT
| FULL TEXT
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management
Wajed et al.
Rheumatology (Oxford) 2004;43:7-12.
FULL TEXT
Prophylaxis of the antiphospholipid syndrome: a consensus report
Alarcon-Segovia et al.
Lupus 2003;12:499-503.
ABSTRACT
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
Erkan et al.
Rheumatology (Oxford) 2002;41:924-929.
ABSTRACT
| FULL TEXT
The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation
Jennekens and Kater
Rheumatology (Oxford) 2002;41:619-630.
ABSTRACT
| FULL TEXT
Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)?
Malaviya and Mourou
Lupus 2000;9:561-562.
|
